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Abstract
Introduction: Studies have found that people with Multiple Sclerosis experience relatively high rates of anxiety and
depression. Although methodologically robust, many of these studies had access to only modest sample sizes (N,200). The
aims of this study were to use responses gained via the web portal of the UK MS Register (N.4000) to: describe the
depression and anxiety profiles of people with MS; to determine if anxiety and depression are related to age or disease
duration; and to assess whether the levels of anxiety and depression differ between genders and types of MS.
Methods: From its launch in May 2011 to the end of December 2011, 7786 adults with MS enrolled to take part in the UK MS
Register via the web portal. The responses to the Hospital Anxiety and Depression Scale (HADS) were collated with basic
demographic and descriptive MS data provided at registration and the resulting dataset was analysed in SPSS (v.16).
Results: The mean HADS score among the 4178 respondents was 15.7 (SE 0.117, SD 7.55) with a median of 15.0 (IQR 11).
Anxiety and depression rates were notably high, with over half (54.1%) scoring $8 for anxiety and 46.9% scoring $8 for
depression. Women with relapsing-remitting MS were more anxious than men with this type (p,0.001), and than women
with other types of MS (p= 0.017). Within each gender, men and women with secondary progressive MS were more
depressed than men or women with other types of MS (p,0.001, p,0.001).
Conclusions: This largest known study of its kind has shown that anxiety and depression are highly prevalent in people with
MS, indicating that their mental health needs could be better addressed. These findings support service planning and
further research to provide the best care for people with MS to help alleviate these debilitating conditions.
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Introduction
Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune
disease. The lifetime risk of major depression in people with MS
has been estimated to be as high as 50% compared to 10 to 15% in
the general population [1,2] Also, studies have variously reported
significantly higher rates of anxiety and depression in people with
MS compared to the general population [1–4]. However, although
methodologically robust, many of these studies used fairly modest
sample sizes (N,200), with far fewer in excess of 400 [1,2]. This
was often because they relied on patients attending a clinic, or
because the studies included other number-limiting factors such as
neuropsychiatric and clinical examinations, or they were part of a
clinical trial [1,2,5–7]. Because of the relatively high prevalence of
anxiety and depression and the debilitation they can cause, we
sought to add to the knowledge base on these conditions in people
with MS using over 4,000 responses to the Hospital Anxiety and
Depression Scale (HADS), gained via the web portal of the UK
MS Register.
The UK MS Register captures data from three main sources
and is able to anonymously link these data at the individual level
whilst retaining privacy. Data are collected directly from people
with MS via a purpose-built web portal, from sources of routine
administrative data, and from patient-management systems
operating in NHS neurology clinics. The web portal has been
collecting data since it was launched in May 2011, and data
collection from clinics and administrative sources is underway. By
uniting data from three disparate sources the UK MS Register
model is innovative in its design and provides new opportunities
for studying MS via linked data. The Register is based on the
proven technologies and robust Information Governance arrange-
ments in place in the Secure Anonymised Information Linkage
(SAIL) system developed by the Health Information Research
Unit (HIRU) [8,9].
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The web portal functions as a questionnaire delivery platform
for people with MS to provide information on their experiences of
living with MS. It hosts a number of validated questionnaires,
including: the Hospital Anxiety and Depression Scale [10], the MS
Disease Impact Scale–29 [11], and the EQ-5D [12]. These cover a
range of topics such as: MS and mental well-being; impact of MS
on daily life; lifestyle and health outcomes. Baseline information
including: age, gender, date of diagnosis of MS, type of MS and
age at onset is collected as part of the registration process. We have
shown that it is feasible to collect information in this way and to
use it to characterize a cohort of people with MS [13].
Research Aims
This is a novel study as it utilized responses received via the web
portal of the UK MS Register to: profile anxiety and depression in
people with MS; to explore the relationships between anxiety and
depression and factors such as age and disease duration; and to
assess whether the levels of anxiety and depression differ between
genders and types of MS. With the relatively large sample size, we
were able to make a reasonably in-depth address of these research
aims, and it is anticipated that the findings will be useful to inform
the mental health care of people with MS and to support further
research.
Methods
Research Ethics and Governance
The UK MS Register study was peer-reviewed via the MS
Society and it received ethical approval from the South West –
Central Bristol Research Ethics Committee (11/SW/0160) as a
research database [14]. Under this ethical approval, data collected
via the portal, the neurology clinics and routine administrative
sources can be anonymously linked using the SAIL methodologies
provided that agreement to the portal terms of service (via the
portal) and written informed participant consent (at the clinics)
have been obtained. The working UK MS Register contains only
anonymous data but with facilities are in place to re-contact
participants to take part in further research [15]. In future, the
Register data will be made accessible for analysis by researchers
external to the team, subject to regulatory and governance
requirements. The final operating model for these arrangements is
yet to be determined, but we are able at accommodate researcher
requests to view the data in the interim, subject to any necessary
amendments to regulatory and governance approvals and a non-
disclosure agreement.
Data Collection and Analysis
Adults with MS living in the UK have been able to enroll on the
web portal of the UK MS Register since its launch in May 2011.
By the end of 2011, 7786 people had registered and data collection
is on-going. The anxiety and depression components of the HADS
are each robust, and the scale has been validated for use with
people who have MS [10,16]. The responses to the HADS
received between May and December 2011 were collated with
basic demographic and descriptive MS data provided at registra-
tion and the resulting dataset was analysed in SPSS (v.16). The
findings were compared with normative data from a large non-
clinical sample as a reference group [17]. Descriptive statistics
were used to characterize the cohort of people with MS with
respect to their anxiety and depression profiles. The continuous
variables were assessed for normality using the Kolmogorov-
Smirnov test and all were found to deviate significantly from the
normal distribution (p,0.001). Because of this, non-parametric
inferential tests were used: Spearman’s rank correlation coefficient
to measure relationships between variables, the Chi square test
was used to assess independence between categories, the Mann-
Whitney U test was used to assess differences between two
independent samples, and the Kruskal-Wallis one-way analysis of
variance was used to compare more than two independent
samples. Significance values are reported in the results and mean
ranks are tabulated in a supplementary file (Table S1). A
Bonferrioni correction was used where relevant to avoid over-
reporting significance where multiple tests were conducted. This
was calculated as the significance level divided by the number of
tests undertaken.
Results
Description of Respondents
Among the respondents, 70.4% were women, 29.3% were men
(2.4 women: 1 man) and 0.3% did not record their gender
(N=4706). The reported types of MS were: 14.4% primary
progressive (PPMS), 61.7% relapsing-remitting (RRMS), 9.4%
secondary progressive (SPMS), and 14.5% didn’t know their type
of MS (DKMS) (N=4540). The timelines and HADS scores of the
respondents were explored using descriptive statistics. The mean
age of the respondents was 50.9 years (SE 0.17, SD 11.5) with a
median of 51.0 years (IQR 16). The mean time from first
Table 1. Timelines and HADS score of people with MS.
N Mean SD SE Median IQR Range
Age (yrs):
All 4617 50.9 11.5 0.17 51.0 16 20 to 87
Male 1355 52.8 11.4 0.31 53.0 17 23 to 87
Female 3253 50.5 11.4 0.20 50.0 16 20 to 84
Time from first
symptoms (yrs):
All 3765 16.7 11.3 0.18 15.0 16 0 to 63
Male 1065 16.9 11.4 0.35 15.0 16 0 to 62
Female 2627 16.6 11.3 0.22 15.0 16 0 to 63
Time since diagnosis
(yrs):
All 2265 12.2 9.4 0.20 10.0 13 0 to 47
Male 655 12.8 9.5 0.37 11.0 14 0 to 47
Female 1566 12.0 9.4 0.24 10.0 13 0 to 46
HADS score:
All 4178 15.7 7.5 0.12 15.0 11 0 to 40
Male 1187 15.6 7.6 0.22 15.0 11 0 to 40
Female 2903 15.7 7.5 0.14 15.0 11 0 to 40
Anxiety score:
All 4381 8.2 4.3 0.07 8.0 6 0 to 21
Male 1247 7.6 4.3 0.12 7.0 7 0 to 21
Female 3040 8.4 4.2 0.08 8.0 6 0 to 21
Depression score:
All 4379 7.6 4.2 0.06 7.0 7 0 to 21
Male 1258 8.0 4.3 0.12 8.0 6 0 to 20
Female 3032 7.3 4.2 0.08 7.0 6 0 to 21
Descriptions of the variables are shown. Slight differences in totals by gender
compared to all are due the small percentages (,2%) of participants for whom
either age or gender was missing.
doi:10.1371/journal.pone.0041910.t001
Anxiety and Depression in People with MS
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Figure 1. Levels of anxiety in people with a depression score .=8. The proportions of people with different levels of anxiety (normal, mild,
moderate or severe) and who have a depression score of 8 or above (N= 1961).
doi:10.1371/journal.pone.0041910.g001
Figure 2. Levels of depression in people with an anxiety score .=8. The proportions of people with different levels of depression (normal,
mild, moderate or severe) and who have an anxiety score of 8 or above (N= 2268).
doi:10.1371/journal.pone.0041910.g002
Anxiety and Depression in People with MS
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experiencing symptoms (disease onset) was 16.7 years (SE 0.16, SD
11.3) with a median of 15.0 years (IQR 16). The mean time since
diagnosis (by a neurologist) was 12.2 years (SE 0.20, SD 9.4) with a
median of 10.0 years (IQR 13). The mean HADS score was 15.7
(SE 0.12, SD 7.5) with a median of 15.0 (IQR 11). The mean
anxiety score was 8.2 (SE 0.07, SD 4.3) with a median of 8.0 (IQR
6). The mean depression score was 7.6 (SE 0.06, SD 4.2) with a
median of 7.0 (IQR 7). In the UK population reference group the
mean values for anxiety and depression were 6.14 (SD 3.8, median
6) and 3.68 (SD 3.1, median 3), respectively [17]. The timelines
and HADS scores are shown in more detail in Table 1, including
the values by gender.
Relationships between Variables
Spearman’s rank correlation coefficient was used to assess
relationships between variables. Little or no relationship was found
between age and HADS score (rho=20.06, p,0.001), or age and
depression score (rho=0.04, p=0.10), but there was a weak
negative relationship between age and anxiety score (rho=20.18,
p,0.001). Similar patterns were seen with time since first
symptoms and time since diagnosis against HADS scores. That
is, there was little or no relationship between time since first
symptoms and HADS score (rho=20.03, not sig), or depression
score (rho= 0.045, p=0.008), but there was a weak negative
relationship with anxiety score (rho=20.10, p,0.001). There was
little or no relationship between time since diagnosis and HADS
score (rho=20.06, p=0.01), or depression score (rho=0.01, not
sig), but there as a weak negative relationship between time since
diagnosis and anxiety score (rho=20.11, p,0.001); Depression
and anxiety scores were positively correlated (rho=0.565,
p,0.001), similar to the reference group (0.53, p,0.001) [17].
As weak negative relationships were observed between the
timeline variables and anxiety scores, tests were conducted to
assess if there were any differences in the pattern of HADS scores
between standard ONS age categories (15 to 24, 25 to 44, 45 to
64, .65 years). A significant difference was found in HADS scores
between the age groups with the youngest age group having the
highest mean ranks and the over 65s having the lowest mean ranks
(p,0.001, N=4096), and the results were similar for anxiety and
age bands (p,0.001, N=4294). Depression scores also differed
between age bands but with a different pattern of mean ranks, the
lowest being in the youngest age group and the highest being in
the 45 to 64 age band (p,0.001, N=4296).
Table 2. Anxiety and depression levels in people with MS.
Categories Anxiety and Depression
Normal Mild Moderate Severe Total
,=7 8–11 12–15 .15
Anxiety levels
Gender
Male: No. 649 277 254 67 1247
% 52.0 22.2 20.4 5.4 100.0
Female: No. 1319 801 749 171 3040
% 43.4 26.3 24.6 5.6 100.0
Depression levels
Gender:
Male: No. 621 285 284 68 1258
% 49.4 22.7 22.6 5.4 100.0
Female: No. 1658 655 621 98 3032
% 54.7 21.6 20.5 3.2 100.0
Anxiety levels
MS type
Primary progressive:
No.
321 144 109 33 607
% 52.9 23.7 18.0 5.4 100.0
Relapsing-remitting:
No.
1137 676 670 132 2615
% 43.5 25.9 25.6 5.0 100.0
Secondary
progressive: No.
192 97 83 26 398
% 48.2 24.4 20.9 6.5 100.0
Don’t know: No. 290 147 131 45 613
% 47.3 24.0 21.4 7.3 100.0
Depression levels
MS type:
Primary progressive:
No.
314 145 124 29 612
% 51.3 23.7 20.3 4.7 100.0
Relapsing-remitting:
No.
1,443 557 521 80 2601
% 55.5 21.4 20.0 3.1 100.0
Secondary
progressive: No.
171 89 117 20 397
% 43.1 22.4 29.5 5.0 100.0
Don’t know: No. 329 132 132 32 625
% 52.6 21.1 21.1 5.1 100.0
Anxiety levels
Depression levels:
Normal: No. 1415 498 251 23 2187
% 64.7 22.8 11.5 1.1 100.0
Mild: No. 316 274 265 37 892
% 35.4 30.7 29.7 4.1 100.0
Moderate: No. 143 227 382 107 859
% 16.6 26.4 44.5 12.5 100.0
Table 2. Cont.
Categories Anxiety and Depression
Normal Mild Moderate Severe Total
,=7 8–11 12–15 .15
Anxiety levels
Severe: No. 13 21 60 58 152
% 8.6 13.8 39.5 38.2 100.0
Anxiety and depression levels by gender and type of MS are shown, and anxiety
and depression levels are compared.
doi:10.1371/journal.pone.0041910.t002
Anxiety and Depression in People with MS
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Frequencies of Anxiety and Depression
Over half of the respondents (54.1%) scored $8 for anxiety and
46.9% scored $8 for depression. The anxiety and depression
scores were separately grouped into the accepted categories of
normal (,=7), mild (8–11), moderate (12–15) and severe (.15)
[18]. These were use to explore the proportional relationships
between anxiety and depression categories against MS type and
gender. Men were more frequently depressed than women: 50.6%
compared to 45.3%, but women were more frequently anxious
than men: 56.4% compared to 48.0%. Anxiety was most frequent
among people with RRMS (56.5%), whereas depression was most
frequent among people with SPMS (56.9%). Inter-relationships
between anxiety and depression categories were also compared: of
the people who were suffering severe anxiety, over half were also
experiencing moderate or severe depression (57.7%); and of the
people who were reporting severe depression, over three-quarters
were also suffering moderate or severe anxiety (77.7%). The
proportions of people suffering from anxiety and depression are
shown in Figures 1 and 2, and further details are shown in Table 2.
Differences in Anxiety and Depression Levels
Mann-Whitney U tests were used to determine if HADS scores
differed significantly between genders, but no significant difference
was found (not sig, N=4090). However, anxiety scores were higher
in women (p,0.001, N=4287) and depression scores were higher
in men (p,0.001, N=4290) (Figures 3 and 4). Kruskall-Wallis tests
were used to assess if HADS scores varied by MS type. These
showed that HADS scores, anxiety scores and depression scores all
varied significantly with MS type, and with differing patterns in
mean ranks: HADS (p,0.03, N=4043), anxiety (p,0.001,
N=4233) and depression (p,0.001, N=4235). (Figures 5 and 6).
It was also noted that the types of MS were not independent of
gender. For men the proportions among the different types of MS
were: 22.0% PPMS, 52.8% RRMS, 12.1% SPMS and 13.1%
DKMS; for women they were: 11.3% PPMS, 65.3% RRMS,
8.2% SPMS and 15.1% DKMS (chi squared p,0.001) (Figures 7
and 8).
These results showed that women are more anxious than men,
and that anxiety is higher in people with RRMS, but greater
proportions of women than men have RRMS. Conversely, men
are more depressed than women, and depression is higher in
people with PPMS and SPMS, but greater proportions of men
than women have PPMS or SPMS. This indicates there may be
some confounding between the variables under test. Additional
tests were conducted to control for this possibility. Firstly Mann-
Whitney U tests were used to compare anxiety and depression
scores (separately) between men and women in each of the MS
types. Then, Kruskall-Wallis tests were used to compare anxiety
and depression scores (separately) between types of MS for each
gender.
Mann Whitney U tests showed that for each of PPMS and
RRMS, women were significantly more anxious than men
(p=0.03, N=606 and p,0.001, N=2609 respectively). Significant
difference was retained for RRMS when a Bonferroni correction
was applied (for a required p value of#0.0125), but not for PPMS.
There was no significant difference in anxiety scores between the
genders for SPMS (not sig, N=396 ) or DKMS (not sig, N=613).
Men with RRMS or DKMS were significantly more depressed
than women (p=0.035, N=2596 and p=0.008, N=625, respec-
tively), but this was not retained when the Bonferroni correction
was applied. There was no significant difference in depression
Figure 3. Anxiety scores for men and women. The anxiety scores for men and women are indicated. It can be seen that the women’s scores are
higher than men’s.
doi:10.1371/journal.pone.0041910.g003
Anxiety and Depression in People with MS
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Figure 4. Depression scores for men and women. The depression scores for men and women are indicated. It can be seen that the men’s scores
are higher than women’s.
doi:10.1371/journal.pone.0041910.g004
Figure 5. Anxiety scores by MS type. The variations in anxiety scores by type of MS are shown.
doi:10.1371/journal.pone.0041910.g005
Anxiety and Depression in People with MS
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scores between the genders for PPMS and SPMS (not sig, N=611
and not sig, N=395, respectively). Kruskall-Wallis tests showed
that there was no significant difference in men’s anxiety scores
between different types of MS (not sig, N=1226), but women’s
anxiety scores differed with type of MS (p=0.017, N=2998) with
the highest levels in RRMS. Depression scores varied with MS
type for men and for women (p,0.001, N=1238 and p,0.001,
N=2989, respectively), with the highest levels in SPMS in men
and women.
Figure 6. Depression scores by MS type. The variations in depression scores by type of MS are shown.
doi:10.1371/journal.pone.0041910.g006
Figure 7. Proportions of MS types among men. The various proportions of MS types reported by the male respondents are shown.
doi:10.1371/journal.pone.0041910.g007
Anxiety and Depression in People with MS
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Discussion
Main Findings
This work used .4000 responses to the HADS questionnaire
gained via the web portal of the UK MS Register to study the
anxiety and depression profiles of people with MS, and to explore
the relationships between anxiety and depression and various
factors that might have an impact on the rates and levels of these
conditions. Within the sample there were a broad range of ages
and MS durations and our respondents were reasonably repre-
sentative of the characteristics of prevalent MS cohorts reported
elsewhere [19–22]. A literature review has shown that the optimal
threshold for indicating likely caseness is $8 for each of anxiety
and depression [23]; over half the respondents in this study scored
$8 for anxiety and almost half scored $8 for depression. This
indicates that, in common with other studies that have compared
anxiety and depression rates in people with MS with those of their
respective general populations [2,5,24], the prevalence rates
observed here are higher than in the general UK population,
and the mean anxiety and depression scores were higher than
those found for the general UK population [17]. Furthermore, the
rates are as high (or higher) as reported by earlier studies of people
with MS [1,2,5,24,25].
As well as differences in frequencies of anxiety and depression,
there were differences in the levels of anxiety and depression
between genders and MS types. Women suffered higher levels of
anxiety than men, and men were more depressed than women.
The levels of anxiety and depression also varied between types of
MS, with anxiety higher in people with RRMS and depression
higher in people with PPMS or SPMS. However, these findings
might be subject to confounding because there were different
distributions of MS types between the genders. Having applied
measures to control for this possibility, it was found that women
with RRMS were more anxious than men with this type, and
more anxious women with other types of MS. Conversely, there
were no significant differences in men’s anxiety levels across the
MS types. For each gender, men and women with SPMS were
more depressed than men or women with other types of MS, and
there were no significant differences in the depression levels of men
and women with PPMS or SPMS.
There was a positive correlation between anxiety scores and
depression scores indicating that the two conditions are related,
and this was also seen in the general population reference group
[17]. Apart from this, the majority of the analyses of linear
relationships, such as age or disease duration against HADS scores
showed little correlation, indicating that the prevalences of anxiety
and depression are generally high across these variables. However,
there were some weak negative relationships between anxiety and
the three timeline variables tested. There were also some
variations in anxiety and depression levels among standard age
groups, with higher levels of anxiety in the 15 to 24 age group, and
lower levels in the over 65 age group, and higher levels of
depression in the 45 to 64 age band. It is likely that these findings
are partly due to population norms, such as the greater prevalence
of anxiety among women compared to men, and varying levels of
anxiety and depression associated with population maturation. But
it is also possible that the findings are partly due to the patterns of
initial diagnosis and disease course. The majority of people are
initially diagnosed with RRMS (up to 85%) and fewer with PPMS
(up to 15%). Over time there can be a sustained build-up of
disability, independent of relapses, so that in about two-thirds of
people with RRMS, the diagnosis may change to SPMS [22].
What this Study Adds
This is the largest known study of this type among people with
MS to be reported on to date. Its novel mode of data collection has
generated a large sample size which has allowed more in-depth,
robust sub-group analysis to be conducted. It has brought new
information on anxiety and depression from the respondents’ own
perspectives. It has shown that anxiety and depression are highly
Figure 8. Proportions of MS types among women. The various proportions of MS types reported by the female respondents are shown.
doi:10.1371/journal.pone.0041910.g008
Anxiety and Depression in People with MS
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prevalent in people with MS and that the rates and levels differ
with various factors. It has provided greater knowledge of the
anxiety and depression profiles of people with MS that can be used
for care planning and research.
Limitations
This study was based on self-reported information and the
respondents were not necessarily a fully representative sample of
people with MS in the UK. Ascertainment is commonly assumed
to be skewed when using web-based data collection methods, as
the technology may pose a barrier to the elderly, disadvantaged,
technically inexperienced or cognitively impaired [26,27]. It is also
possible that help-seeking behavior among people experiencing
anxiety and depression is leading to a greater apparent prevalence
of these conditions. Any response bias in portal data will be
addressable using the linkable data from clinical sites and routine
sources, as the Register continues to build up an increasingly rich
picture of MS in the UK.
Future Work
Future work will analyse the responses to other questionnaires
delivered via the platform, to study impact on daily life, influence
of lifestyle factors, medication records and health outcomes for
people with MS. We will be able to study the responses to the
HADS questionnaire in association with self-reported medication
records to explore the relationships between anxiety and
depression and medicines in use. Data for the Register continues
to be collected, and we will link self-reported information with
clinical and administrative Register data to compare information
between the data sources. For example, we aim to use the Register
make a more in-depth study of anxiety in people with MS, since it
has been noted that this is under-studied compared to depression
[1]. We will also be able to study the relationships between
disability and mental well-being. As well as this, a programme of
qualitative research is underway to engage with people with MS to
improve our understanding of their needs in contributing to the
Register [28].
Conclusion
The notably high rates and levels of anxiety and depression
among people with MS found in this study indicate that their
mental health needs could be better addressed. The importance of
appropriate mental health treatment and care and their potential
to improve quality of life for people with MS has been highlighted
[29,30]. The disease course of MS can be highly unpredictable
and each case must be managed individually, so it is important for
service planners to be reflective of the potential additional demand
for mental health services as well as other medical and
rehabilitative care. The findings of this study may be used to
support service planning and further research to provide the best
outcomes for people with MS to help alleviate these debilitating
conditions.
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